SCHEMBL8767795

SCHEMBL8767795

O=C(N/N=C/c1cccc(/C=N/NC(=O)c2ccccc2)c1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.72
HDAC2 Q92769 1/20 0.72
HDAC8 Q9BY41 1/20 0.72
NCOR2 Q9Y618 1/20 0.72
KMT2A Q03164 6/20 0.69
MEN1 O00255 5/20 0.69
RAB9A P51151 4/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
NPC1 O15118 3/20 0.69
CYP1A2 P05177 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
CYP3A4 P08684 1/20 0.67
POLB P06746 2/20 0.66
TDP1 Q9NUW8 2/20 0.66
PLEC Q15149 1/20 0.66
CTDSP1 Q9GZU7 1/20 0.66
ASF1A Q9Y294 1/20 0.64
ESRRG P62508 1/20 0.63
CASP3 P42574 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12305537 0.93 RAB9A (0.73) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL2830919 0.91 RAB9A (0.81) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL711754 0.91 RAB9A (0.81) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL711755 0.91 RAB9A (0.81) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL8771684 0.91 RAB9A (0.85) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL13475714 0.89 RAB9A (0.74) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL31622507 0.89 RAB9A (0.78) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL30170995 0.89 RAB9A (0.78) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL13475715 0.89 POLB (0.84) HDAC3HDAC2HDAC8NCOR2KMT2A
SCHEMBL27178008 0.89 RAB9A (0.78) HDAC3HDAC2HDAC8NCOR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161755-A1 Metal-Organic Frameworks (MOFs), Method For Their Preparation And Their Application UNIWERSYTET JAGIELLONSKI (PL) 2018-06-14 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL HDAC3 4338/4885HDAC2 4610/4885HDAC8 3359/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HDAC3 3607/4885HDAC2 3708/4885HDAC8 1812/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HDAC3 3607/4885HDAC2 3708/4885HDAC8 1812/4885
US-20180161755-A1 Metal-Organic Frameworks (MOFs), Method For Their Preparation And Their Application DCX, MDH2, PDHA2 HDAC3 322/4885HDAC2 34/4885HDAC8 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.